Infolettre
HTA Quarterly Summer 2026
In this edition, we look at how health economic and outcomes research (HEOR) teams can use AI to streamline quality appraisals and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) compliance checks, highlighting what a closed-system Generative AI (GenAI) chatbot can reliably support and where expert judgment remains essential. We also broaden the perspective on value, exploring how innovative treatments are increasingly assessed for their wider societal and environmental impacts beyond direct clinical outcomes. Finally, we turn to Germany, sharing insights from a Cencora-sponsored initiative leveraging approved access to the National Cancer Registry (ZfKD) to enable clinically granular oncology research under rigorous governance and data protection requirements.
Heard on the street
"We're seeing first signs of delayed introductions into Europe."
- Stefan Oelrich, President of the European Federation of Pharmaceutical Industries and Associations. U.S. policy has led drugmakers to delay launching some medicines in Europe, where healthcare spending is lower, to avoid putting downward pressure on prices in the $700 billion U.S. market.
Source: Drugmakers delay some European launches with a wary eye on Trump's pricing policies | Reuters
Source: Drugmakers delay some European launches with a wary eye on Trump's pricing policies | Reuters
HTA by the numbers
15
Number of ongoing Joint Clinical Assessments (JCAs). The Coordination Group on Health Technology Assessment (HTACG) estimates that it will initiate ~50 JCAs of medicines in 2026.
List of Ongoing Joint Clinical Assessments - European Commission
Health Technology Assessment – 2026 Work Programme adopted
List of Ongoing Joint Clinical Assessments - European Commission
Health Technology Assessment – 2026 Work Programme adopted
Entrez en contact avec notre équipe
Notre équipe d’experts de la valeur se consacre à la transformation des données probantes, des informations sur les politiques et des renseignements sur le marché en stratégies efficaces d’accès au marché mondial. Laissez-nous vous aider à naviguer dans le paysage complexe des soins de santé d’aujourd’hui en toute confiance. Contactez-nous pour découvrir comment nous pouvons vous aider à atteindre vos objectifs.
